Programmed death ligand-1 expression and occult lymph node metastasis in non-small cell lung cancer

被引:0
|
作者
Mitsui, Suguru [1 ]
Tanaka, Yugo [1 ]
Jimbo, Naoe [2 ]
Doi, Takefumi [1 ]
Tane, Shinya [1 ]
Hokka, Daisuke [1 ]
Maniwa, Yoshimasa [1 ]
机构
[1] Kobe Univ, Div Thorac Surg, Grad Sch Med, 7-5-2 Kusunoki Cho, Chuou Ku, Kobe, Hyogo 6500017, Japan
[2] Kobe Univ, Dept Diagnost Pathol, Grad Sch Med, Kobe, Japan
关键词
non-small cell lung cancer; occult lymph node metastasis; PD-L1; expression; PD-L1; EXPRESSION; ASSOCIATION; PATHWAY;
D O I
10.1111/1759-7714.14922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Identifying the preoperative risk factors for lymph node upstaging could contribute to the development of individualized perioperative treatment for patients with non-small cell lung cancer (NSCLC). The current study aimed to evaluate the risk factors for lymph node upstaging, including gene mutation and programmed death ligand-1 expression in patients with resectable NSCLC.Methods Data on the clinicopathological characteristics of patients who underwent lobectomy for clinical N0 NSCLC at our institution were collected. The clinicopathological findings of the pathological N0 and lymph node upstaging groups were then analyzed. Univariate and multivariate analyses were performed to examine the predictive factors for nodal upstaging.Results Of 291 patients, 40 had postoperative nodal upstaging (n = 25, N1; n = 15, N2). Large tumor size and high maximum standardized uptake value were significantly associated with nodal upstaging. The nodal upstaging group had a higher proportion of patients with solid adenocarcinoma and lymphatic, vascular, and pleural invasion than the pathological N0 group. Further, the nodal upstaging group had a higher proportion of patients with positive programmed death ligand-1 expression than the pathological N0 group. Univariate and multivariate analyses showed that tumor size and positive programmed death ligand-1 expression were associated with nodal upstaging.Conclusion The appropriate therapeutic strategy including preoperative treatment and resection should be cautiously considered preoperatively in patients with clinical N0 NSCLC who have large tumors and positive programmed death ligand-1 expression.
引用
收藏
页码:1774 / 1781
页数:8
相关论文
共 50 条
  • [1] Programmed death ligand-1 expression in non-small cell lung cancer
    Velcheti, Vamsidhar
    Schalper, Kurt A.
    Carvajal, Daniel E.
    Anagnostou, Valsamo K.
    Syrigos, Konstantinos N.
    Sznol, Mario
    Herbst, Roy S.
    Gettinger, Scott N.
    Chen, Lieping
    Rimm, David L.
    LABORATORY INVESTIGATION, 2014, 94 (01) : 107 - 116
  • [2] Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Schalper, Kurt
    Carvajal, Daniel
    Chen, Lieping
    Sznol, Mario
    Gettinger, Scott N.
    Herbst, Roy S.
    Rimm, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Correlation of Programmed Cell Death Ligand-1 Messenger RNA and Protein Expression in Non-Small Cell Lung Cancer
    Kwon, H. J.
    Kim, H.
    Park, S. Y.
    Park, E.
    Chung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2243 - S2244
  • [4] Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer
    Popple, Amy
    Illidge, Timothy M.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S553 - S556
  • [5] Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer in Mexican Population and Correlation with Clinicopathologic Features
    Bornstein, L.
    Macedo-Perez, O.
    Lyra Gonzalez, I.
    Bautista-Wong, C.
    Cienfuegos-Meza, J.
    Campos-Peralta, K.
    Jimenez-Fuentes, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S504 - S505
  • [6] Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer
    Pang, Chen
    Yin, Limei
    Zhou, Xiaojuan
    Lei, Chuanfen
    Tong, Ruizhan
    Huang, Meijuan
    Gong, Youling
    Ding, Zhenyu
    Xue, Jianxin
    Zhu, Jiang
    Wang, Yongsheng
    Ren, Li
    Zhou, Lin
    Wang, Jin
    Peng, Feng
    Zhou, Qiao
    Lu, You
    JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 816 - 824
  • [7] Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
    Yu, Hui
    Brustugun, Odd Terje
    Ekman, Simon
    Botling, Johan
    La Fleur, Linnea
    Micke, Patrick
    Solberg, Steinar
    Berglund, Anders
    Rivard, Christopher
    Hirsch, Fred R.
    CLINICAL LUNG CANCER, 2021, 22 (04) : E555 - E562
  • [8] Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer
    Naoko Shigeta
    Shuji Murakami
    Kouji Yamamoto
    Tomoyuki Yokose
    Tetsuya Isaka
    Kota Washimi
    Yohei Miyagi
    Haruhiro Saito
    Hiroyuki Ito
    Aya Saito
    Journal of Cancer Research and Clinical Oncology, 151 (4)
  • [9] Programmed Death Ligand-1 (PD-L1) Expression in Patients with Non-Small Cell Lung Cancer (NSCLC) with Unusual Metastasis: A Case Series
    Tsugitomi, R.
    Nishimura, N.
    Imai, R.
    Okafuji, K.
    Kitamura, A.
    Tomishima, Y.
    Jinta, T.
    Suzuki, K.
    Tamura, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [10] A Comparison of Five Different Immunohistochemistry Assays for Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer Samples
    Soo, Ross
    Lim, Joey
    Asuncion, Bernadette Reyna
    Fazreen, Zul
    Herrera, Maria
    Omar, Feroz
    Seet, Ju Ee
    Bryne, David
    Hendry, Shona
    Fox, Stephen
    Soong, Richie
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S801 - S801